You can find the annual or quarterly income statement of Conduit Pharmaceuticals Inc here for insights into the performance and operational efficiency of Conduit Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Operating expenses
-39.38%3.00M
-8.81%3.66M
502.22%21.16M
21.03%7.03M
57.71%4.95M
35.67%4.01M
292.51%3.51M
443.59%5.81M
82.88%3.14M
47.16%2.96M
-46.54%895.00K
14.58%1.07M
555.34%1.72M
590.03%2.01M
--1.67M
--933.00K
--262.00K
--291.00K
R&D expenses
-83.76%302.00K
-40.57%778.00K
465.15%746.00K
-50.47%1.53M
7340.00%1.86M
922.66%1.31M
46.67%132.00K
--3.09M
--25.00K
--128.00K
--90.00K
-100.00%0.00
----
----
----
--38.00K
----
----
Depreciation, depletion, and amortization
-43.59%471.00K
188.95%549.00K
13.94%515.00K
17600.00%885.00K
--835.00K
--190.00K
--452.00K
--5.00K
----
----
----
----
----
----
----
----
----
----
Other operating expenses
----
----
----
----
----
----
----
----
----
----
----
----
----
----
---47.00K
--120.00K
----
----
Operating profit
39.38%-3.00M
8.81%-3.66M
-502.22%-21.16M
-21.03%-7.03M
-57.71%-4.95M
-35.67%-4.01M
-292.51%-3.51M
-443.59%-5.81M
-82.88%-3.14M
-47.16%-2.96M
46.54%-895.00K
-14.58%-1.07M
-555.34%-1.72M
-590.03%-2.01M
---1.67M
---933.00K
---262.00K
---291.00K
Net non-operating interest income (expenses)
Non-operating interest income
----
-100.00%0.00
350.00%9.00K
--7.00K
100.00%4.00K
-11.11%8.00K
-86.67%2.00K
----
--2.00K
--9.00K
--15.00K
----
----
----
----
----
----
----
Non-operating interest expense
-70.18%17.00K
-72.16%49.00K
-96.04%38.00K
-84.47%48.00K
-52.10%57.00K
47.90%176.00K
705.88%959.00K
557.45%309.00K
205.13%119.00K
2280.00%119.00K
--119.00K
--47.00K
--39.00K
--5.00K
----
----
----
----
Gains from sale of securities
--0.00
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Return on equity
---86.00K
---68.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
---1.52M
-390.00%-290.00K
--178.00K
--0.00
----
--100.00K
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
98.04%-20.00K
99.90%-1.00K
-115.41%-318.00K
87.10%-44.00K
51.88%-1.02M
-98.97%-969.00K
-25.70%2.06M
-110.99%-341.00K
-182.71%-2.13M
-220.39%-487.00K
298.85%2.78M
13586.96%3.10M
-158.42%-752.00K
-850.00%-152.00K
---1.40M
---23.00K
---291.00K
---16.00K
Income before tax
23.01%-4.64M
21.05%-4.06M
-786.33%-21.32M
-10.17%-7.12M
-11.98%-6.03M
-44.88%-5.15M
-235.24%-2.41M
-425.33%-6.46M
-114.63%-5.38M
-64.06%-3.55M
157.93%1.78M
307.74%1.99M
-353.53%-2.51M
-605.21%-2.17M
---3.07M
---956.00K
---553.00K
---307.00K
Income tax
----
----
---4.56M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
23.01%-4.64M
21.05%-4.06M
-786.33%-21.32M
-10.17%-7.12M
-11.98%-6.03M
-44.88%-5.15M
-235.24%-2.41M
-425.33%-6.46M
-114.63%-5.38M
-64.06%-3.55M
157.93%1.78M
307.74%1.99M
-353.53%-2.51M
-605.21%-2.17M
---3.07M
---956.00K
---553.00K
---307.00K
Net income from continuous operations
23.01%-4.64M
21.05%-4.06M
-786.33%-21.32M
-10.17%-7.12M
-11.98%-6.03M
-44.88%-5.15M
-235.24%-2.41M
-425.33%-6.46M
-114.63%-5.38M
-64.06%-3.55M
157.93%1.78M
307.74%1.99M
-353.53%-2.51M
-605.21%-2.17M
---3.07M
---956.00K
---553.00K
---307.00K
Net income attributable to controlling interests
23.01%-4.64M
21.05%-4.06M
-786.33%-21.32M
-10.17%-7.12M
-11.98%-6.03M
-44.88%-5.15M
-235.24%-2.41M
-425.33%-6.46M
-114.63%-5.38M
-64.06%-3.55M
157.93%1.78M
307.74%1.99M
-353.53%-2.51M
-605.21%-2.17M
---3.07M
---956.00K
---553.00K
---307.00K
Net income attributable to common shareholders
23.01%-4.64M
21.05%-4.06M
-786.33%-21.32M
-10.17%-7.12M
-11.98%-6.03M
-44.88%-5.15M
-235.24%-2.41M
-425.33%-6.46M
-114.63%-5.38M
-64.06%-3.55M
157.93%1.78M
307.74%1.99M
-353.53%-2.51M
-605.21%-2.17M
---3.07M
---956.00K
---553.00K
---307.00K
Basic earnings per share
99.92%-8.71
-180.00%-55.62
-532.57%-204.01
-195.90%-329.03
95.00%-5.46
72.47%-19.86
-188.48%-32.25
-344.17%-111.19
-94.63%-109.33
-48.81%-72.17
153.00%36.45
312.75%45.54
-353.39%-56.17
-605.90%-48.49
---68.78
---21.41
---12.39
---6.87
Diluted earnings per share
99.92%-8.71
-180.00%-55.62
-532.57%-204.01
-195.90%-329.03
95.00%-5.46
72.47%-19.86
-188.48%-32.25
-346.85%-111.19
-94.63%-109.33
-48.81%-72.17
153.00%36.45
310.44%45.05
-353.39%-56.17
-605.90%-48.49
---68.78
---21.41
---12.39
---6.87
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
FAQs
How do I read Conduit Pharmaceuticals Inc's income statement on TradingKey?
Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.
What is the difference between quarterly and annual income statements?
A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.
What does YOY mean on the income statement page?
YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.
Which income statement metrics matter most when analyzing CDT stock?
Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.
What was Conduit Pharmaceuticals Inc's net income for the year?
Conduit Pharmaceuticals Inc posted -39.22M in net income for fiscal year 2025.
How much net income did Conduit Pharmaceuticals Inc post in the last quarter?
Conduit Pharmaceuticals Inc reported -4.64M in net income for the latest quarter。
What was Conduit Pharmaceuticals Inc's annual operating profit?
Conduit Pharmaceuticals Inc's operating income was -36.76M for fiscal year 2025.
How is EPS related to the income statement?
EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.